aav2/8lsphgaa
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03533673)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Acidic alpha-glucosidaseSupplementation
GAA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03533673 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Asklepios BIoPharmaceutical, Duke University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asklepios BIoPharmaceutical | For profit | 1 | 1 | 1 | 2018 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1